Clinigen and Shionogi formalize licensing pact for cefiderocol

Clinigen has entered a new phase of collaboration with Japanese drugmaker Shionogi (TYO: 4507), signing a licensing agreement for cefiderocol that sets the stage for potential market entry in Australia and New Zealand.

The agreement gives Clinigen’s Australian subsidiary, Link Medical Products, exclusive rights to develop and commercialize the antibiotic across both countries. Regulatory review is already underway in Australia, with the Therapeutic Goods Administration accepting the market authorisation application for cefiderocol in December last year.

Under the terms, Shionogi will receive an upfront payment, development-related milestones, and royalties tied to commercial performance. Neither company disclosed the financial details. Clinigen chief executive Jerome Charton described the collaboration as a “pivotal moment” that aligns with the group’s commitment to tackling antimicrobial resistance in a region where market access is evolving.